Firm at a glance
Quadria Capital is a platform private equity firm with over US$4 billion in assets under management, per its website [S1].
What they buy
Quadria Capital focuses exclusively on healthcare investments across Asia, as evidenced by its portfolio composition [S2]. The firm’s observed sectors include healthcare delivery providers, life sciences companies, medical device manufacturers, and associated healthcare services businesses [S2]. Recent platform acquisitions span dialysis services, ophthalmology hospitals, and orthopedic device companies, suggesting a preference for specialized healthcare verticals with consolidation potential [S3].
Portfolio
Healthcare Delivery
NephroPlus (platform, acquired 2024) and Maxivision Eye Hospitals (platform, acquired 2023) [S3].
Life Sciences
Apex Healthcare, Aragen Life Sciences, and Encube Ethicals [S2].
Medical Devices
Straits Orthopaedics (platform, acquired 2023) [S3].
Associated Healthcare Services
MediBuddy and Nobel Hygiene [S2].
Recent activity (last 24 months)
* **February 2026**: Completed take-private acquisition of Apex Healthcare in Malaysia for approximately $470 million [S4].
* **May 2025**: Closed oversubscribed Fund III at US$1 billion [S5].
How this firm fits a seller
Quadria Capital appears suited for healthcare business owners in Asian markets seeking a sector-specialist buyer with dedicated capital and regional operating experience. The firm’s pattern of platform acquisitions in specialized healthcare verticals suggests it targets founder-owned or family-owned businesses positioned for geographic or service-line expansion [S2][S3]. For sellers of healthcare delivery, life sciences, or medical device companies operating in Asia, Quadria’s exclusive healthcare focus and recent fund close indicate active acquisition capacity as of 2025 [S5].
Sources
[S1] https://quadriacapital.com/about-quadria-capital (as of 2025-01-15)
[S2] https://quadriacapital.com/portfolio (as of 2025-01-15)
[S3] https://quadriacapital.com (as of 2025-01-15)
[S4] https://www.financeasia.com/article/quadria-capital-completes-malaysias-apex-healthcare-470m-take-private-deal/507291 (as of 2026-02)
[S5] https://www.businesswire.com/news/home/20250526456856/en/Quadria-Capital-Closes-Oversubscribed-US%241-Billion-Fund-III-to-Advance-Healthcare-Transformation-Across-Asia (as of 2025-05-27)
Frequently asked questions
Does Quadria Capital buy healthcare businesses?
Yes, Quadria Capital invests exclusively in healthcare businesses across Asia, per its portfolio and public disclosures [S1][S2]. The firm’s observed sectors include healthcare delivery, life sciences, medical devices, and associated healthcare services [S2].
What companies has Quadria Capital acquired recently?
Recent acquisitions include Apex Healthcare, a Malaysian life sciences company acquired in February 2026 for approximately $470 million [S4], and NephroPlus, a healthcare delivery platform acquired in 2024 [S3]. The firm also acquired Maxivision Eye Hospitals and Straits Orthopaedics as platforms in 2023 [S3].
Where is Quadria Capital based and how big is the firm?
Quadria Capital manages over US$4 billion in assets under management, per its website [S1]. The firm closed its third fund at US$1 billion in May 2025 [S5]. Specific headquarters location was not disclosed in available public sources as of January 2025.
Is Quadria Capital still actively acquiring?
Yes, Quadria Capital appears actively acquiring based on its February 2026 completion of the Apex Healthcare transaction [S4] and its May 2025 close of a US$1 billion fund dedicated to healthcare investments across Asia [S5].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.